The treament, developed by GSK and Vir Biotechnology, has shown to cut the risk of hospitalization or death by 79% in adults with mild-to-moderate COVID-19.
Source

JOIN NCOV.LINK NEWSLETTER

And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.